Cincera Therapeutics Overview
- Founded
- 2018
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $5.56M
- Investors
- 1
Cincera Therapeutics General Information
Description
Developer of inflammatory and fibrotic illness drug intended to cure metabolic diseases. The company's drug treats difficult-to-treat inflammatory and fibrotic conditions associated with obesity, it also has applicability in many other disease areas including cancer, and liver problems, enabling doctors to cure patients effectively.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- Melbourne, Victoria
- Australia
Cincera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC | 19-Feb-2018 | $5.56M | 00.000 | Completed | Startup |
Cincera Therapeutics Executive Team (3)
Cincera Therapeutics Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ben Atcliffe Ph.D | Cincera Therapeutics | Board Member | 000 0000 |
| Katherine Nielsen | Cincera Therapeutics | Board Member | 000 0000 |
| Melissa McBurnie Ph.D | Self | Chairman | 000 0000 |
| Michael Bettess Ph.D | Self | Executive Director & Board Member | 000 0000 |
Cincera Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Brandon Capital Partners | Venture Capital | Minority | 000 0000 | 000000 0 |